Clinical trials
-
Advanced Solid Tumours – Anti-HER3 ADC
Read more: Advanced Solid Tumours – Anti-HER3 ADCFirst-in-Human, Phase 1 Study of AMT-562, an Anti-HER3 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
-
Urothelial Cancer – BT8009 Monotherapy or Combo
Read more: Urothelial Cancer – BT8009 Monotherapy or ComboA Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer
-
Advanced Solid Tumors – BG-C477 – High CEA
Read more: Advanced Solid Tumors – BG-C477 – High CEAA Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors
-
Gastric and Solid Tumours – AB598
Read more: Gastric and Solid Tumours – AB598A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants with Advanced Malignancies
-
Advanced Solid Tumours – STAT3 inhibitor – VVD-130850
Read more: Advanced Solid Tumours – STAT3 inhibitor – VVD-130850A Phase 1, Open-Label, 2-Part, Multicenter, First-in-Human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of the STAT3 inhibitor VVD-130850 as Single Agent and in Combination with Checkpoint Inhibition in Participants with Advanced Solid and Hematologic Tumors
-
Breast cancer – Metastatic Her2 positive
Read more: Breast cancer – Metastatic Her2 positiveJZP598-303: A Phase 3, randomized, open-label, multicenter, controlled study to evaluate the efficacy and safety of zanidatamab in combination with physician’s choice chemotherapy compared to trastuzumab in combination with physician’s choice chemotherapy for the treatment of participants with metastatic HER2-positive breast cancer who have progressed on, or are intolerant to, previous trastuzumab deruxtecan treatment.
-
Advanced Solid Tumours – BG-68501 – selective CDK2 Inhibitor
Read more: Advanced Solid Tumours – BG-68501 – selective CDK2 InhibitorA Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
-
Colorectal and Solid Tumours – PARP1 Inhibitor M9466 with Topoisomerase 1 Inhibitor-based regimens
Read more: Colorectal and Solid Tumours – PARP1 Inhibitor M9466 with Topoisomerase 1 Inhibitor-based regimensA Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of the PARP1 Inhibitor M9466 in Combination with Topoisomerase 1 Inhibitor-based Regimens in advanced solid tumours and colorectal cancer.